Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

5-HT & MEDICATION DEVELOPMENT FOR METHAMPHETAMINE ABUSE

Award Number: R01DA015760
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/28/2003
PERIOD OF PERFORMANCE END DATE: 05/31/2010

Group Awards By:

View Award Description

5-HT & MEDICATION DEVELOPMENT FOR METHAMPHETAMINE ABUSE - DESCRIPTION (provided by applicant): Recent years have witnessed an alarming increase in the abuse of methamphetamine (METH), a potent psychomotor stimulant associated with a high incidence of drug relapse in the drug-withdrawn addict. To date, there is no pharmacotherapy that effectively reduces this relapse frequency. The Overall Objective of this grant is to identify putative drug treatments in the pre-clinical setting that can rapidly translate into post-withdrawal pharmacotherapy for the human METH addict. Repeated, intermittent exposure of animals to drugs of abuse causes behavioral and neurobiological changes that may model the neuroadaptive processes that contribute to drug relapse in humans. Behavioral sensitization, characterized by an enduring enhancement in motor behavior that persists for weeks to months after the drug is withdrawn, is common to METH and other drugs of abuse. However, the effects of a behaviorally sensitizing regimen of METH on cellular signaling and gene transcription have not been well studied. Our preliminary data demonstrate that (1) rats behaviorally sensitized to METH exhibit an upregulation of serotonin 5-HT2A/2C receptor -mediated signaling, and (2) post-withdrawal administration of the 5-HT2A/2C antagonist, mianserin, negates the sensitized motor behaviors established by METH. These findings direct our hypotheses that 1) increases in 5-HT2A/2C - function parallels METH-induced behavioral sensitization, and 2) 5-HT2A/2C antagonists can oppose behavioral sensitization and its associated neuroadaptive changes when the antagonists are administered after sensitized responding has developed. Experiments in Aim I will establish a METH dosing paradigm that exhibits an enduring behavioral sensitization (lasting 60 days after withdrawal) with a minimum of neurotoxicity to be used for the remaining studies. Aim II will determine the ability of three clinically available non-selective 5-HT2A/2C antagonists, mianserin, mirtazapine and ketanserin to negate METH-induced behavioral sensitization. The comparative effectiveness of antagonist administration at early and late stages of post-sensitization withdrawal will be ascertained. Aim Ill will establish, across time and brain region, changes in 5-HT receptor signaling, gene transcription (e.g., phosphorylated cAMP response element binding protein) and cellular physiology (e.g., in vivo electrophysiology with microiontophoresis) associated with persistent behavioral sensitization, and its attenuation as caused by post-withdrawal 5-HT antagonist treatments. Aim IV will ascertain the efficacy of newer, 5-HT2A or 5-HT2C -selective antagonists to negate METH-induced behavioral and cellular sensitization. These studies will provide new and important preclinical data for the development of medications targeted towards assisting the drug-withdrawn METH addict to stay drug free.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2009 ( Subtotal = $0 )
2009	2007	RUSH-PRESBYTERIAN-ST LUKE'S MEDICAL CENTER	1700 WEST VAN BUREN STREET	CHICAGO	IL	60612	COOK	USA	Drug Use and Addiction Research Programs	000	6	8/24/2009	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2007 ( Subtotal = $331,352 )
2007	2007	RUSH-PRESBYTERIAN-ST LUKE'S MEDICAL CENTER	1700 WEST VAN BUREN STREET	CHICAGO	IL	60612	COOK	USA	Drug Use and Addiction Research Programs	000	6	6/8/2007	NON-COMPETING CONTINUATION	$331,352
														Subtotal = $331,352

Issue Date FY: 2006 ( Subtotal = $342,384 )
2006	2006	LOYOLA UNIVERSITY MEDICAL CENTER	820 N MICHIGAN AVENUE	CHICAGO	IL	60611	COOK	USA	Drug Use and Addiction Research Programs	000	4	8/28/2006	NON-COMPETING CONTINUATION	$342,384
														Subtotal = $342,384

Issue Date FY: 2005 ( Subtotal = $351,720 )
2005	2005	LOYOLA UNIVERSITY MEDICAL CENTER							Drug Use and Addiction Research Programs	000	3	5/25/2005	NON-COMPETING CONTINUATION	$351,720
														Subtotal = $351,720

Issue Date FY: 2004 ( Subtotal = $348,435 )
2004	2004	LOYOLA UNIVERSITY MEDICAL CENTER							Drug Use and Addiction Research Programs	000	2	4/28/2004	NON-COMPETING CONTINUATION	$348,435
														Subtotal = $348,435

Issue Date FY: 2003 ( Subtotal = $341,891 )
2003	2003	LOYOLA UNIVERSITY MEDICAL CENTER	2160 SOUTH FIRST AVENUE	MAYWOOD	IL	60153	COOK	USA	Drug Use and Addiction Research Programs	000	1	9/30/2003	NEW	$341,891
														Subtotal = $341,891

Grand Total All Awards = $1,715,782

Top

All Categories

About

Search

Reports

Data Submission

Award Information

5-HT & MEDICATION DEVELOPMENT FOR METHAMPHETAMINE ABUSE

Award Number: R01DA015760

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/28/2003

PERIOD OF PERFORMANCE END DATE: 05/31/2010

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer